Language assessment has a crucial role in the clinical diagnosis of several neurodegenerative diseases. 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Identifying individuals destined to develop Alzheimer's dementia within time frames acceptable for clinical trials constitutes an important challenge to design studies to test emerging disease-modifying therapies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
47/100
The method presented in this paper can be used to separate stable MCI patients from those who are at early stages of AD dementia with high accuracy. 2 key findings →
Participants: 86 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This technique could be applied to questions in social gerontology related to how social media outlets reflect and shape attitudes bearing on other developmental outcomes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The concomitant decline in stroke and dementia incidence rates may depict how successful stroke prevention has targeted shared risk factors of both conditions, especially at advanced ages where such risk factors are highly prevalent. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
With the publication in 2015 of the consensus statement by the perfusion study group of the International Society for Magnetic Resonance in Medicine (ISMRM) and the EU-COST action 'ASL in dementia' on the implementation of arterial spin labelling MRI (ASL) in a clinical setting, the development of ASL can be considered to have become mature and ready for clinical prime-time. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Subjects with Alzheimer's disease (AD) show loss of cognitive functions and change in behavioral and functional state affecting the quality of their daily life and that of their families and caregivers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Through various manifestations, social inappropriateness is frequently the first clinical sign of a neurodegenerative process, especially in AD and bvFTD, years before noticeable impairment on classical neuropsychological assessment and brain atrophy on imaging. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Longer age-related decision making latencies may reflect a greater need for working memory and increased self-monitoring in older subjects. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
One in 8 patients presented with moderate speech timing deficits with a further two-thirds rated as mild or subclinical. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Primary Progressive Aphasia (PPA) is a neurodegenerative condition characterized by insidious irreversible loss of language abilities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Random Forest and LASSO were found to be optimal methods for feature selection. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
41/100
Using subset of optimal features in SVM, we classified MCI-C from MCI-NC with an accuracy, sensitivity, specificity, and the area under the receiver operating characteristic (ROC) curve of 91.4%, 83.24%, 90.1%, and 0.95, respectively. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies on brain imaging analysis witnessed the core roles of machine learning techniques in computer-assisted intervention for brain disease diagnosis. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings may suggest potential deficiencies in ambulatory care and postdischarge care related to managing comorbidities among Medicare fee-for-service ADRD patients. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The European Medical Information Framework initiative supports EHR data on unprecedented number of people with dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
The modern antiretroviral treatment of human immunodeficiency virus (HIV-1) infection has considerably lowered the incidence of opportunistic infections. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This collaboratively developed, person-centred model can support the design of new education and training tools and be readily translated into existing programmes. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Technological advances will catalyze groundbreaking discoveries for effective treatments of neurodegenerative cognitive disorders, such as AD, and inform novel strategies for dementia prevention and sustained lifelong cognitive health. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The accurate diagnosis of Alzheimer's disease (AD) and its early stage, i.e., mild cognitive impairment, is essential for timely treatment and possible delay of AD. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
We developed a comprehensive set of quality indicators of appropriate and inappropriate end-of-life care in people with Alzheimer's disease, cancer or chronic obstructive pulmonary disease, to be used in population-level research. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The early motor manifestations of sporadic amyotrophic lateral sclerosis (ALS), while rarely documented, reflect failure of adaptive complex motor skills. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →